Aprea Therapeutics, Inc. APRE
Aprea Therapeutics, Inc. (Nasdaq: APRE) is an oncology drug developer. Its lead program, APR-1051, is in Phase 1 for PPP2R1A-mutated endometrial cancer (uterine serous carcinoma) and cyclin E-overexpressing platinum-resistant ovarian cancer. Its next catalyst on record is APR-1051: Clinical data update at 38th EORTC-NCI-AACR Symposium (November 2026).
Upcoming catalysts
- November 2026APR-1051 — Clinical data update at 38th EORTC-NCI-AACR Symposium
We expect to report the next clinical data update from ACESOT-1051 at the 38th EORTC-NCI-AACR Symposium in November 2026.
Next further out: APR-1051 — Enrollment acceleration to 6-10 patients per month (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| APR-246 (eprenetapopt) | Undisclosed (discontinued program) | small molecule | Phase 3 |
| ATRN-119 | Undisclosed (ATR inhibitor for oncology) | small molecule | Phase 2 |
| APR-1051 | PPP2R1A-mutated endometrial cancer and cyclin E-overexpressing platinum-resistant ovarian cancer | small molecule | Phase 1 |
Recent results and decisions
- May 6, 2026positive APR-1051 achieved a confirmed partial response in a patient with uterine carcinosarcoma harboring PPP2R1A mutation, with treatment ongoing at 140 days.
Best Response: Confirmed Partial Response (PR) • PR (-50%) at first assessment Feb 10, 2026 • Confirmed PR with additional -9.5% reduction from C3D1 Mar 10, 2026
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.